Trial Outcomes & Findings for Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence (NCT NCT00223236)
NCT ID: NCT00223236
Last Updated: 2014-08-11
Results Overview
Urine drug screens were administered at each visit to detect cocaine in urine. If negative according to urine analysis, it is determined as no cocaine use and if positive, cocaine use. Percentage of participants with no cocaine detected in urine at exit is an outcome measuring treatment effectiveness. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks.
COMPLETED
PHASE3
44 participants
Biweekly (visit) urine drug screens
2014-08-11
Participant Flow
Patients were recruited from local community behavioral healthcare clinics and through advertising in local publications. The recruitment period was from 5/1/2004 to 4/12/2005.
Participants were randomized to medication assignment after meeting the inclusion and exclusion criteria and completing the Institutional Review Board(IRB)-approved informed consent process.
Participant milestones
| Measure |
Citicoline
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
|
Placebo
Inactive ingredient matching the active medication in appearance
|
|---|---|---|
|
Overall Study
STARTED
|
16
|
18
|
|
Overall Study
COMPLETED
|
9
|
4
|
|
Overall Study
NOT COMPLETED
|
7
|
14
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence
Baseline characteristics by cohort
| Measure |
Citicoline
n=23 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
|
Placebo
n=21 Participants
Inactive ingredient matching the active medication in appearance
|
Total
n=44 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
23 Participants
n=99 Participants
|
21 Participants
n=107 Participants
|
44 Participants
n=206 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Age, Continuous
|
42.1 years
STANDARD_DEVIATION 6.6 • n=99 Participants
|
40.7 years
STANDARD_DEVIATION 8.0 • n=107 Participants
|
41.4 years
STANDARD_DEVIATION 7.1 • n=206 Participants
|
|
Sex: Female, Male
Female
|
10 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
21 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
13 Participants
n=99 Participants
|
10 Participants
n=107 Participants
|
23 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
23 participants
n=99 Participants
|
21 participants
n=107 Participants
|
44 participants
n=206 Participants
|
|
Inventory of Depressive Symptomatology
|
43.6 Units on a scale
STANDARD_DEVIATION 10.6 • n=99 Participants
|
38.7 Units on a scale
STANDARD_DEVIATION 13 • n=107 Participants
|
41.26 Units on a scale
STANDARD_DEVIATION 11.9 • n=206 Participants
|
|
Young Mania Rating Scale
|
11.2 Units on a scale
STANDARD_DEVIATION 4.9 • n=99 Participants
|
11.5 Units on a scale
STANDARD_DEVIATION 7.0 • n=107 Participants
|
11.34 Units on a scale
STANDARD_DEVIATION 5.89 • n=206 Participants
|
|
Rey Auditory Verbal Learning Scale
|
36.6 T scores
STANDARD_DEVIATION 10.0 • n=99 Participants
|
36.0 T scores
STANDARD_DEVIATION 9.0 • n=107 Participants
|
36.33 T scores
STANDARD_DEVIATION 9.47 • n=206 Participants
|
|
cocaine used
No cocaine used
|
19 participants
n=99 Participants
|
19 participants
n=107 Participants
|
38 participants
n=206 Participants
|
|
cocaine used
Cocaine used
|
4 participants
n=99 Participants
|
1 participants
n=107 Participants
|
5 participants
n=206 Participants
|
|
cocaine used
Unknown
|
0 participants
n=99 Participants
|
1 participants
n=107 Participants
|
1 participants
n=206 Participants
|
PRIMARY outcome
Timeframe: Biweekly (visit) urine drug screensPopulation: Number of participants are those who completed baseline assessment and at least one treatment visit followed by baseline.
Urine drug screens were administered at each visit to detect cocaine in urine. If negative according to urine analysis, it is determined as no cocaine use and if positive, cocaine use. Percentage of participants with no cocaine detected in urine at exit is an outcome measuring treatment effectiveness. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks.
Outcome measures
| Measure |
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
|
Placebo
n=18 Participants
Inactive ingredient matching the active medication in appearance
|
|---|---|---|
|
Cocaine Use Determined by Urine Analysis
|
62.50 percentage of participants no cocaine
|
50.00 percentage of participants no cocaine
|
SECONDARY outcome
Timeframe: Change in scores between baseline and exit (exit - baseline).Population: Number of participants reported are those who completed baseline assessment and at least one treatment visit.
The IDS-SR is a 30 item self report used to assess the severity of depressive symptoms. The each item has a 4-likert scale, 0 to 3, with 3 representing the worst symptom. The total score of IDS-SR is calculated as a sum of each item score. The range of possible score is between 0 and 90, 0 as no symptom and 90 the worst symptom. The higher the score, the more severe the depression. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the tudy period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline).
Outcome measures
| Measure |
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
|
Placebo
n=18 Participants
Inactive ingredient matching the active medication in appearance
|
|---|---|---|
|
Inventory of Depressive Symptomatology Self Report (IDS-SR).
|
-20.54 units on scale
Standard Deviation 14.56
|
-11.89 units on scale
Standard Deviation 14.45
|
SECONDARY outcome
Timeframe: Baseline to exit (exit score - baseline score)Population: Numbers of participants are those who completed baseline assessment and at least one treatment visit.
The YMRS questionnaire has 11 items with scale range 0 to 4 for 7 items and 0 to 8 for 4 items. 0=normal and and 4 or 8 =most abnormal. The total possible score is 0 to 60, 0 being no symptom and 60 the worst symptom. The higher the score, the worse the mania symptoms are. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in scores between baseline and exit (exit - baseline).
Outcome measures
| Measure |
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
|
Placebo
n=18 Participants
Inactive ingredient matching the active medication in appearance
|
|---|---|---|
|
Young Mania Rating Scale(YMRS).
|
-2.00 units on a scale
Standard Deviation 8.03
|
-2.88 units on a scale
Standard Deviation 5.68
|
SECONDARY outcome
Timeframe: Change in T scores between baseline and exit (exitT score - baseline T score).Population: number of participants are calculated based on those who completed baseline and at least one treatment visit.
The RAVLT consists of 15 nouns read aloud for five consecutive trials with each trial followed by a free-recall trial. The total score is the total number of words recalled through the five trials. Normative RAVLT T-scores was used. the higher T score, the better memory. Exit week is defined as the last week of treatment. It varied between 2 week an 12 weeks with an average exit week of 10 week and 7 week for the citicoline treatment and placebo groups, respectively. Allowing unequal week of treatment period in measuring outcome enables us to include most participants due to a low retention rate in the end of the study period, 12 weeks. The outcome was measured by change in RAVLT T scores between baseline and exit (exit - baseline).
Outcome measures
| Measure |
Citicoline
n=16 Participants
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
|
Placebo
n=17 Participants
Inactive ingredient matching the active medication in appearance
|
|---|---|---|
|
Rey Auditory Verbal Learning Test(RAVLT)
|
7.06 T score
Standard Deviation 11.79
|
3.14 T score
Standard Deviation 7.07
|
Adverse Events
Citicoline
Placebo
Serious adverse events
| Measure |
Citicoline
n=23 participants at risk
Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects.
|
Placebo
n=21 participants at risk
Inactive ingredient matching the active medication in appearance
|
|---|---|---|
|
Skin and subcutaneous tissue disorders
Skin rash
|
4.3%
1/23 • Number of events 1
|
4.8%
1/21 • Number of events 1
|
|
Psychiatric disorders
Hypomania
|
0.00%
0/23
|
4.8%
1/21 • Number of events 1
|
Other adverse events
Adverse event data not reported
Additional Information
E. Sherwood Brown, M.D., Ph.D., Professor
The University of Texas Southwestern Medical Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place